Compare Aegon Ltd. (AEG) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Aegon Ltd. vs Recursion Pharmaceuticals Inc — how do they compare? Aegon Ltd. trades at $8.73 (market cap $12.98B), while Recursion Pharmaceuticals Inc trades at $3.7 (market cap $2.04B). The key difference: Aegon Ltd. is far larger — about 6.4× Recursion Pharmaceuticals Inc's market cap, and Aegon Ltd. pays a 5.3% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AEG | RXRX | |
|---|---|---|
Market Cap | $12.98B | $2.04B |
Sector | Financials | Health |
52-Week High | $8.79 | $6.79 |
52-Week Low | $6.79 | $2.84 |
Enterprise Value | $14.11B | $1.46B |
Dividend Yield | 5.3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AEG trades at $8.75, up 1.04% on the day, with a P/E of 12.86 and P/S of 0.55 indicating potential undervaluation. Recent earnings show mixed results, beating estimates in Q2 and Q3 2025 but missing in Q4. The company is undergoing strategic simplification, including moving its legal seat to Delaware and focusing on U.S. operations, supported by a dividend of $0.25 payable in July 2026. Technical indicators are bullish on moving averages but neutral on oscillators.
Outlook is cautiously optimistic with a 27.78% analyst buy rating, driven by restructuring benefits and U.S. market focus. Risks include execution challenges in the transition, volatile cash flows, and competitive pressures. The stock presents a value opportunity if the strategic pivot succeeds, but investors should monitor earnings consistency and debt management.
RXRX trades at $3.96, up 4.21% today, with a bullish technical signal from moving averages despite overbought RSI readings. The company shows improving quarterly EPS beats but faces deep losses with a -851.51% net margin. Recent news highlights its AI-driven drug discovery platform and inclusion in Cathie Wood's portfolio (The Motley Fool, 2026-07-05).
Analyst consensus is mixed with 40% buy ratings and a $7.83 price target suggesting significant upside, but high cash burn and negative profitability pose substantial risks. Investment appeal hinges on successful clinical advancements offsetting current financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Aegon Ltd.
Aegon is a Netherlands-headquartered insurance company with core operations that stretch across the U.S., Netherlands, and United Kingdom. The business also holds peripheral ventures in Spain, Portugal, Brazil, and China.
Read more on AEG →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
